PDL BIOPHARMA, INC.

Delisted

CIK 882104fmd_1KAV0HNHK1PX2A6K9T6GTDHTCQManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2008 to Dec 31, 2020, 48 periods

Income Statement · Annual · Millions · USD
Line item	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019
Total revenues	345	362	381	456	581	590	244	91	32	31
Rental revenue	–	–	–	–	–	–	–	–	6	5
Cost of revenue	–	0	0	6	0	0	4	12	14	17
Gross profit	–	362	381	451	581	590	240	79	18	13
Realized investment gains (losses)	–	–	–	–	–	–	0	0	1	0
Research and development	–	–	–	–	0	0	4	1	3	7
Selling, general and administrative	–	–	–	–	35	36	40	39	40	45
Total operating expenses	134	18	25	30	35	40	115	53	66	82
Operating income	211	344	355	427	546	550	129	38	(34)	(51)
Interest expense	44	36	29	25	39	27	18	20	12	11
Other non-operating income (expense)	(61)	(36)	(28)	(25)	(45)	(20)	(20)	(9)	(5)	(10)
Income before taxes	150	307	327	402	501	530	109	29	(40)	(61)
Income tax expense	58	108	115	137	179	197	46	15	(7)	(4)
Net income from continuing operations	92	199	212	265	322	333	64	13	(33)	(57)
Net income	92	199	212	265	322	333	64	111	(69)	(70)
Net income to common shareholders	97	205	212	265	322	333	64	111	(69)	(70)